The Boston Red Sox have bolstered their starting rotation by signing left-hander Ranger Suárez to a five-year, $130 million contract. This move addresses key weaknesses exposed in the 2025 season and positions Boston for a stronger 2026 campaign. The deal includes a signing bonus and options for future years.
The Boston Red Sox announced the finalization of a major contract with free-agent pitcher Ranger Suárez on Wednesday, adding significant depth to their pitching staff amid an active offseason. The agreement, valued at $130 million over five years, comes with a $3 million signing bonus payable within 30 days of Major League Baseball's approval. Suárez will earn $7 million in 2026, $15 million in 2027, $30 million each in 2028 and 2029, and $35 million in 2030. The contract also features a $35 million mutual option for 2031, backed by a $10 million buyout.
This signing is part of Boston's efforts to overhaul a rotation that struggled in 2025 beyond its core performers. While Garrett Crochet, Brayan Bello, and Lucas Giolito delivered solid seasons, the rest of the starters combined for a 5.18 ERA and 1.8 fWAR across 76 games, contributing to a 33-43 record in those outings. Ill-fated additions like Walker Buehler and a down year from Tanner Houck, who posted an 8.04 ERA over nine starts, highlighted the need for reliable arms.
Suárez, previously with the Philadelphia Phillies, brings proven experience to the mix. The Red Sox now project a formidable top five in Crochet, Suárez, Sonny Gray (acquired via trade from the St. Louis Cardinals), Johan Oviedo (from the Pittsburgh Pirates), and Bello. This depth extends further with prospects and additions like Peyton Tolle, Connelly Early, Kutter Crawford, Patrick Sandoval, and Kyle Harrison, catapulting Boston's rotation to the top in projected fWAR for 2026.
The move underscores chief baseball officer Craig Breslow's strategy to target upgrades at critical positions, following trades for Gray and Oviedo. For Suárez, departing Philadelphia after they lost ace Zack Wheeler to a season-ending blood clot issue late in 2025, this represents a lucrative pivot to a contender seeking rotation stability.
